+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
NDDS in Cancer Therapy Market by Product Type, Drug Type, Application, Technology Platform - Global Forecast to 2030- Product Image
NDDS in Cancer Therapy Market by Product Type, Drug Type, Application, Technology Platform - Global Forecast to 2030- Product Image
Sale

NDDS in Cancer Therapy Market by Product Type, Drug Type, Application, Technology Platform - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888824
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The NDDS in Cancer Therapy Market is emerging as a pivotal segment in precision oncology, highlighted by advances in nanoparticle drug delivery and driven by evolving research, regulatory adaptation, and industry partnerships. Senior decision-makers require actionable insights to navigate this complex terrain and drive strategic growth in an increasingly innovative sector.

Market Snapshot: NDDS in Cancer Therapy Market

The NDDS in Cancer Therapy Market grew from USD 11.75 billion in 2024 to USD 13.35 billion in 2025. It is expected to continue growing at a CAGR of 13.38%, reaching USD 24.98 billion by 2030. This expansion is underpinned by sustained R&D, rapid adoption of advanced drug delivery platforms, and resilient industry responses to global supply and regulatory dynamics.

Scope & Segmentation

This report offers a comprehensive analysis across critical dimensions and stakeholder priorities:

  • Product Types: Dendrimers, exosomes, lipid nanocarriers, liposomes, metallic nanoparticles, micelles, nanoemulsions, and polymeric nanoparticles.
  • Drug Types: Gene therapy agents, monoclonal antibodies, oligonucleotide drugs, SiRNA therapies, and small-molecule chemotherapeutics.
  • Applications: Chemotherapy, immunotherapy, photodynamic therapy, radiotherapy, targeted therapy.
  • Technology Platforms: Implantable depot systems, injectable suspensions, microneedle systems, active targeting (ligand targeted and receptor mediated), and passive targeting nanotechnologies.
  • Regions: Americas (notably United States, Canada, Mexico, Brazil, and Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, among others), and Asia-Pacific (covering China, India, Japan, Australia, South Korea, and other major pharmaceutical hubs).
  • Key Companies: Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, AstraZeneca PLC, Merck & Co., Inc., Bristol-Myers Squibb Company, Sanofi S.A., Amgen Inc., AbbVie Inc.

Key Takeaways for Senior Decision-Makers

  • Nanoparticle-driven cancer therapies are steadily advancing, enabled by precision-engineered carriers and integration with diagnostic and genomic tools.
  • Personalized medicine is accelerating demand for tailored NDDS platforms, aligning therapy selection with patient-specific biomarkers and clinical profiles.
  • Partnership models—ranging from strategic biopharma alliances to CDMO collaborations—are instrumental in expanding access to specialized capabilities and accelerating commercial timelines.
  • AI-driven process optimization is enhancing formulation screening and predictive analytics, supporting faster development cycles and robust product pipelines.
  • Regulatory environments are evolving, with expedited pathways for next-generation delivery technologies encouraging faster clinical adoption and competitive positioning.
  • Geographic nuances require localization strategies, especially in rapidly developing Asia-Pacific markets and diverse regulatory landscapes across Europe, Middle East & Africa.

Tariff Impact: Navigating Trade Shifts in Nanocarrier Innovation

Recent US tariffs on critical nanocarrier precursors and manufacturing equipment have impacted production costs and supply chain reliability. To adapt, procurement and manufacturing leaders are prioritizing local sourcing, dual-supplier frameworks, and investment in modular continuous manufacturing. These strategies are essential to maintain operational continuity and manage risk arising from shifting trade policies. Enhanced regulatory scrutiny of process changes and increased capital allocation for in-house capacity have also become significant industry themes.

Methodology & Data Sources

This research is anchored in both primary and secondary data. Expert interviews with leaders spanning oncology, material science, regulatory affairs, and manufacturing provided current industry perspectives. Rigorous secondary review of scientific publications, patent databases, and regulatory filings ensures analytical robustness and industry relevance. Data underwent validation through triangulation, consistency audits, and peer review to guarantee accuracy and traceability.

Why This Report Matters

  • Enables informed decision-making with in-depth market segmentation and actionable strategic insights tailored for R&D, business development, and investment leaders.
  • Provides clarity on external factors shaping market performance, including technology adoption, regulatory trends, and global supply chain challenges in the NDDS in Cancer Therapy Market.
  • Supports competitive positioning through comprehensive coverage of leading platforms, regional nuances, and key industry alliances.

Conclusion

With the NDDS in Cancer Therapy Market entering a phase of structured growth and innovation, organizations that respond to evolving technologies and global dynamics will secure future leadership. This report equips decision-makers with the clarity needed to guide strategic investments and realize the next wave of patient-centric cancer solutions.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. NDDS in Cancer Therapy Market, by Product Type
8.1. Introduction
8.2. Dendrimers
8.3. Exosomes
8.4. Lipid Nanocarriers
8.5. Liposomes
8.6. Metallic Nanoparticles
8.7. Micelles
8.8. Nanoemulsions
8.9. Polymeric Nanoparticles
9. NDDS in Cancer Therapy Market, by Drug Type
9.1. Introduction
9.2. Gene Therapy Agents
9.3. Monoclonal Antibodies
9.4. Oligonucleotide Drugs
9.5. SiRNA
9.6. Small-Molecule Chemotherapeutics
10. NDDS in Cancer Therapy Market, by Application
10.1. Introduction
10.2. Chemotherapy
10.3. Immunotherapy
10.4. Photodynamic Therapy
10.5. Radiotherapy
10.6. Targeted Therapy
11. NDDS in Cancer Therapy Market, by Technology Platform
11.1. Introduction
11.2. Implantable Depot Systems
11.3. Injectable Suspensions
11.4. Microneedle Systems
11.5. Nanotechnology
11.5.1. Active Targeting
11.5.1.1. Ligand Targeted
11.5.1.2. Receptor Mediated
11.5.2. Passive Targeting
12. Americas NDDS in Cancer Therapy Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa NDDS in Cancer Therapy Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific NDDS in Cancer Therapy Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Johnson & Johnson
15.3.2. F. Hoffmann-La Roche Ltd
15.3.3. Pfizer Inc.
15.3.4. Novartis AG
15.3.5. AstraZeneca PLC
15.3.6. Merck & Co., Inc.
15.3.7. Bristol-Myers Squibb Company
15.3.8. Sanofi S.A.
15.3.9. Amgen Inc.
15.3.10. AbbVie Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. NDDS IN CANCER THERAPY MARKET MULTI-CURRENCY
FIGURE 2. NDDS IN CANCER THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. NDDS IN CANCER THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NDDS IN CANCER THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPID NANOCARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY METALLIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOEMULSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GENE THERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY OLIGONUCLEOTIDE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SIRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SMALL-MOLECULE CHEMOTHERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMPLANTABLE DEPOT SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICRONEEDLE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIGAND TARGETED, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RECEPTOR MEDIATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PASSIVE TARGETING, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 56. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 58. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 62. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 63. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 89. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 90. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 93. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 95. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 96. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 99. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 101. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 107. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 109. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 111. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 113. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 114. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 115. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 117. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 119. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 120. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 123. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 127. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 130. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 132. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 135. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 137. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 139. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 141. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 143. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 144. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 145. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 147. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 148. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 149. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 151. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 153. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 154. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 155. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 157. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 159. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 160. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 161. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 163. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 165. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 173. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 175. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 177. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 179. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 180. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 181. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 183. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 184. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 191. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 192. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 193. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 194. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 195. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 196. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 197. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 199. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 201. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 202. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 203. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 204. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 205. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 207. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 208. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 216. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 217. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 218. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 220. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 222. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 223. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 224. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 226. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 228. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 230. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 232. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 233. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 252. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 254. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 255. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 256. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 258. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 259. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 260. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 262. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 263. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 270. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 272. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 274. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 275. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 278. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 280. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 281. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 282. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 283. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 284. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 286. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 287. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2030 (USD MILLION)
TABLE 288. NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2024
TABLE 289. NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this NDDS in Cancer Therapy market report include:
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Sanofi S.A.
  • Amgen Inc.
  • AbbVie Inc.

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 13.35 Billion
Forecasted Market Value ( USD ) by 2030 $ 24.98 Billion
Compound Annual Growth Rate13.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

NDDS in Cancer Therapy - Global Strategic Business Report - Product Image

NDDS in Cancer Therapy - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Cancer Gene Therapy Market by Vector Type, Therapy Type, Indication, Stage, End User - Global Forecast to 2030 - Product Image

Cancer Gene Therapy Market by Vector Type, Therapy Type, Indication, Stage, End User - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Immunotherapy Drugs Market by Therapy Type, Indication, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030 - Product Image

Immunotherapy Drugs Market by Therapy Type, Indication, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030

  • Report
  • 193 Pages
  • Global
From
Liver Cancer Drug Market Size, Share & Trends Analysis Report by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), Type (Hepatocellular Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Region, and Segment Forecasts 2025-2030 - Product Image

Liver Cancer Drug Market Size, Share & Trends Analysis Report by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), Type (Hepatocellular Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Region, and Segment Forecasts 2025-2030

  • Report
  • 100 Pages
  • Global
From
Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Disease Indication, By Route Of Administration, By Drug Class, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Disease Indication, By Route Of Administration, By Drug Class, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.